Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists. Hoth’s innovative pipeline includes The BioLexa Platform, a proprietary, patented antimicrobial therapy being developed for the treatment of Atopic Dermatitis. In addition, the company has other ongoing pre-clinical stage development programs aimed at treating other indications such as asthma, acne, lupus, psoriasis as well as two potential treatments for COVID-19 as well as a medical testing device for COVID-19.